HIGH COURT OF AUSTRALIA
GLEESON CJ,
GAUDRON, McHUGH, GUMMOW, KIRBY, HAYNE AND CALLINAN JJAKTIEBOLAGET HÄSSLE & ANOR APPELLANTS
AND
ALPHAPHARM PTY LIMITED RESPONDENT
Aktiebolaget Hässle v Alphapharm Pty Limited [2002] HCA 59
12 December 2002
S287/2001ORDER
1. Appeal allowed with costs.
2. Set aside orders made by the Full Court of the Federal Court on 9 October 2000.
3. Matter remitted to the Full Court for the determination of any remaining grounds on the respondent's Notice of Contention.
4. Order 2 made by Lehane J on 18 June 1999 dealing with revocation further stayed until further order of the Federal Court.
5. Costs of the whole of the proceedings in the Federal Court to be in the discretion of the Full Court.
On appeal from the Federal Court of Australia
Representation:
J McL Emmerson QC with D M Yates SC and K J Howard for the appellants (instructed by Minter Ellison)
A C Bennett SC with S C G Burley and C Dimitriadis for the respondent (instructed by Mallesons Stephen Jaques)
Notice: This copy of the Court's Reasons for Judgment is subject to formal revision prior to publication in the Commonwealth Law Reports.
GLEESON CJ, GAUDRON, GUMMOW AND HAYNE JJ. The appellants appeal from a decision of the Full Court of the Federal Court[1]. They are members of the Astra pharmaceutical group which is based in Sweden. The first appellant is the patentee of Australian Standard Patent No 601,974 for an invention entitled "New Pharmaceutical Preparation for Oral Use" ("the Patent"). At the time of the grant, the Patents Act 1952 (Cth) ("the 1952 Act") was in force. The term of the Patent is for 20 years from 23 April 1987. The claimed priority date, apparently pursuant to s 141 of the 1952 Act, is 30 April 1986. This was the date of the basic application in the United Kingdom and the Australian application was made on 23 April 1987, that is to say, within the 12 months of the basic application as required by s 141. The second appellant is an Australian subsidiary of the Astra group and is the exclusive licensee of the Patent. It is convenient to refer to the appellants without distinction as "Astra".
[1]Aktiebolaget Hässle v Alphapharm Pty Ltd (2000) 51 IPR 375; [2000] AIPC ¶91‑636.
The Patent
The Patent claims an oral pharmaceutical preparation in the form of a tablet, capsule or pellet containing omeprazole as the active ingredient. Omeprazole is a compound first synthesised in 1979. When absorbed in the upper part of the small intestine it inhibits gastric fluid secretions, and is useful in the treatment of gastric and duodenal ulcers. Astra held Standard Patent No 529,654 under the 1952 Act for this compound ("the compound patent"). This patent has expired and was not in suit in the present litigation.
The discovery of omeprazole and the grant of the compound patent was not itself sufficient to bring about the commercial exploitation of the compound by…
Keep reading for free
Create a free CaseChat account to read Aktiebolaget Hassle v Alphapharm Pty Ltd and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2002] HCA 59
- Decision Date
CaseChat Overview and Summary
The central legal issue before the High Court was whether the primary judge had erred in law in concluding that the patent was invalid for obviousness. This required the court to consider the principles of patentability, specifically the inventive step requirement, and how they applied to a pharmaceutical formulation arrived at after experimental research. The court also had to determine the relevance of publications discoverable by a routine literature search but not part of the common general knowledge in Australia at the priority date, and whether an invention is obvious if a skilled worker would have considered it "worthwhile to try" its constituent elements.
The High Court's reasoning focused on the primary judge's assessment of the evidence regarding the perceived incompatibility between the enteric coat and the acid-labile omeprazole. The primary judge had noted that no evidence was presented of prior encounters with such a problem, nor of any existing products where this issue had been addressed. Furthermore, evidence indicated that other acid-labile drugs had been successfully enteric coated, and that experts would have initially attempted a direct enteric coating. The court considered the significant experimental work undertaken by Astra, including extensive human trials over several years, and the fact that even an expert tasked with developing the formulation did not arrive at the claimed invention without considerable effort and multiple reports. This extensive research and the lack of prior art suggesting the problem or its solution were key factors in the court's assessment of obviousness.
The High Court allowed the appeal, setting aside the orders of the Full Court of the Federal Court. The matter was remitted to the Full Court for determination of any remaining grounds of appeal, and the revocation order was further stayed. Costs were to be in the discretion of the Full Court.
Orders
Orders of the court
1. Appeal allowed with costs.
2. Set aside orders made by the Full Court of the Federal Court on 9 October 2000.
3. Matter remitted to the Full Court for the determination of any remaining grounds on the respondent's Notice of Contention.
4. Order 2 made by Lehane J on 18 June 1999 dealing with revocation further stayed until further order of the Federal Court.
5. Costs of the whole of the proceedings in the Federal Court to be in the discretion of the Full Court.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
Established by: GLEESON CJ, GAUDRON, GUMMOW AND HAYNE JJ,
Full text does not contain this section.